caa a22 4500 477072054 CHVBK 20180405111429.0 cr unu---uuuuu 170330e19960701xx s 000 0 eng 10.1007/BF02627954 doi (NATIONALLICENCE)springer-10.1007/BF02627954 Renin Inhibitors: Cardiovascular drugs of the future? [Elektronische Daten] [Jeanette Wood, Philippe Close] Summary: This review explores whether the therapeutic attractiveness of renin inhibitors compared with angiotensinconverting enzyme (ACE) inhibitors and angiotensin II receptor antagonists, is sufficient to warrant continued interest in their development for the treatment of cardiovascular discase. Clinical and experimental data available to date indicate that patients with hypertension and congestive heart failure will benefit from renin inhibition. However, clinical experience is very limited, and extra benefits of renin inhibitors compared with the other blockers of the reninangiotensin system (RAS) have yet to be demonstrated. Some experimental data in animals and humans point to a greater effect of acute renin inhibition on renal blood flow than other modes of interference with the RAS. Again, the clinical benefits of such an effect, and particularly after long-term treatment, in hypertension and renal disease need to be determined. In today's cost-conscious health setting, only new drugs that bring additional clinical benefits have a good chance of being commercially viable. It remains to be seen whether renin inhibitors will fulfill these criteria. Kluwer Academic Publishers, 1996 renin-angiotensin system nationallicence hypertension nationallicence congestive heart failure nationallicence renal disease nationallicence angiotensin-converting enzyme inhibition nationallicence Wood Jeanette Pharmaceutical Division, CIBA Geigy, Ltd., CH 4002, Basle, Switzerland aut Close Philippe Pharmaceutical Division, CIBA Geigy, Ltd., CH 4002, Basle, Switzerland aut Cardiovascular Drugs and Therapy Kluwer Academic Publishers 10/3(1996-07-01), 309-312 0920-3206 10:3<309 1996 10 10557 https://doi.org/10.1007/BF02627954 text/html Onlinezugriff via DOI 1 review-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02627954 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Wood Jeanette Pharmaceutical Division, CIBA Geigy, Ltd., CH 4002, Basle, Switzerland aut NATIONALLICENCE 700 1- Close Philippe Pharmaceutical Division, CIBA Geigy, Ltd., CH 4002, Basle, Switzerland aut NATIONALLICENCE 773 0- Cardiovascular Drugs and Therapy Kluwer Academic Publishers 10/3(1996-07-01), 309-312 0920-3206 10:3<309 1996 10 10557 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer